Delivery Order SPE2DB24D1021-SPE2DB25FFAGT
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,703.95 to AmerisourceBergen Drug Corp for the supply of Amlodipine-Valsartan 10-320 mg tablets (30-count units) on August 22, 2025, with completion targeted for August 25, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Amlodipine-Valsartan 5-160 mg tablets (30-count) under a firm fixed-price contract valued at $1,129.61. The order was competitively awarded without set-aside designation and is scheduled for completion by August 1, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate office location. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Amlodipine-Valsartan 5-160 mg tablets (30-count units) valued at $23,768.80. This competitively awarded, non-set-aside delivery order employs firm fixed pricing and is scheduled for completion by September 17, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency has awarded a delivery order valued at $8,336.56 to AmerisourceBergen Drug Corp for the supply of Amlodipine-Valsartan 10-160 mg tablets (30-count packages). This firm fixed-price, non-set-aside contract was awarded on August 25, 2025, with an ultimate completion date of August 26, 2025, and will be performed at the vendor's Corporate Office location in Conshohocken, Pennsylvania. Amlodipine-Valsartan is a combination antihypertensive medication used in the treatment...
- The Defense Logistics Agency awarded a $1,337.76 delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of AMLODIPINE-VALSARTAN-HYDROCHLOROTHIAZIDE 10-320-25 MG in a 30-count package. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, due for completion by September 8, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Valsartan-HCL 320-25 mg tablets in quantities of 90 units, with a ceiling value of $6,299.54 and a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that authorizes the...
- The Defense Logistics Agency awarded a delivery order valued at $6,531.30 to AmerisourceBergen Drug Corp for the supply of Valsartan-HCT 160-12.5 mg tablets (90-count) on September 16, 2025, with an ultimate completion date of September 17, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract involves...
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, valued at $1,812.56, for the supply of Amlodipine-Valsartan 10-160 mg tablets (30-count supply) with an ultimate completion date of August 27, 2025. This non-set-aside contract represents a routine pharmaceutical procurement executed through the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $11,424.98 to AmerisourceBergen Drug Corp for the supply of AMLODIPINE-VALSARTAN-HYDROCHLOROTHIAZIDE 5-160-12.5 mg tablets in a 30-count quantity. This competitive, non-set-aside award was executed on August 7, 2025, with an ultimate completion date of August 8, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The firm fixed price delivery order structure reflects the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Valsartan-HCTZ 160-25 mg tablets in quantities of 90 units, with a contract ceiling value of $11,676.65. This is a firm fixed-price delivery order with an ultimate completion date of September 17, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FFAGTDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Amlodipine-Valsartan 10-320 mg tablets (30-count supply) with a ceiling value of $1,936.74. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures. The contract is set to conclude on September 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical supplier to federal military and veteran healthcare systems. The company holds extensive federal contract awards with the DLA Medical Supply Chain, delivering a comprehensive portfolio of pharmaceutical products including brand-name and generic medications across multiple therapeutic domains. The current delivery order for this combination antihypertensive medication supports the Defense Health Agency and broader military healthcare programs. AmerisourceBergen's proven capability in competitively awarded federal medical procurement, demonstrated through consistent performance across diverse product categories and transaction values, positions it as a key vendor within DLA's planned Pharmaceutical Prime Vendor Global Program Generation V, which will involve multiple regional awards across several contractors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 9/5/25 |